NASDAQ:LIXT Lixte Biotechnology (LIXT) Stock Forecast, Price & News $1.95 +0.20 (+11.43%) (As of 09/20/2023 ET) Add Compare Share Share Today's Range$1.81▼$2.2550-Day Range$1.75▼$7.5352-Week Range$1.58▼$27.00Volume198,032 shsAverage Volume21,434 shsMarket Capitalization$4.39 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Lixte Biotechnology (NASDAQ:LIXT) StockLixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to design novel compounds for serious common diseases. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.Read More LIXT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LIXT Stock News HeadlinesAugust 27, 2023 | wsj.comLixte Biotechnology Holdings Inc. WtJuly 20, 2023 | finance.yahoo.comLIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq RulesSeptember 21, 2023 | Wall Street Fundamentals (Ad)How is This "Hidden Gem" Thriving in a Turbulent Market?While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.July 18, 2023 | benzinga.comWhy Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionJuly 18, 2023 | msn.comLIXTE Biotechnology falls after company launches $3.5M registered direct offering of sharesJuly 18, 2023 | marketwatch.comLixte Bio Shares Tumble 31% After Pricing $3.5M Stock OfferingJuly 18, 2023 | finance.yahoo.comLIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq RulesJuly 17, 2023 | marketwatch.comLixte Biotechnology Shares Rise 25% on LB-100 Cancer Treatment ResearchSeptember 21, 2023 | Wall Street Fundamentals (Ad)How is This "Hidden Gem" Thriving in a Turbulent Market?While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.July 17, 2023 | msn.comWhat's Going On With Lixte Biotechnology (LIXT) Stock?July 17, 2023 | finance.yahoo.comPreclinical Results of LIXTE Biotechnology’s Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE’s Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and ChemotherapyJune 23, 2023 | finance.yahoo.comLIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing RequirementsJune 7, 2023 | finance.yahoo.comLIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTE’s Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue SarcomasJune 5, 2023 | finance.yahoo.comOwning 53% in Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) means that insiders are heavily invested in the company's futureJune 2, 2023 | msn.comLIXTE Biotechnology Holdings announces reverse stock split to obtain minimum price complianceJune 2, 2023 | marketwatch.comLixte Biotech Shares Down 8% After Company Announces Reverse Stock SplitJune 2, 2023 | finance.yahoo.comLIXTE Biotechnology Holdings, Inc. Announces 1-for-10 Reverse Stock Split of its Common Stock Effective on Pre-Market Opening on June 5, 2023May 30, 2023 | finance.yahoo.comRecently Published Independent Research Reveals New Mechanisms by Which LIXTE Biotechnology’s Lead Clinical Compound, LB-100, Increases Effectiveness of Cancer ImmunotherapyMay 12, 2023 | marketwatch.com8-K: LIXTE BIOTECHNOLOGY HOLDINGS, INC.April 28, 2023 | marketwatch.comGlobal Neurometabolic Disorders Market Share 2023-2030 with On-going Demand StatusApril 24, 2023 | finance.yahoo.comLIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE's Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue SarcomaApril 4, 2023 | finance.yahoo.comLIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hope’s Ongoing Phase 1b Clinical Trial in Evaluating Lixte’s Lead Anti-Cancer Compound, LB-100, in Small Cell Lung CancerMarch 24, 2023 | marketwatch.comGaucher Disease Drugs Market Top Players By 2031March 21, 2023 | marketwatch.comProtein Phosphatase 2A Market Top Players and Forecast till 2028February 21, 2023 | marketwatch.comGaucher Disease Drugs Market Massive Growth Strikes Due To Technological Innovation During 2023-2028February 14, 2023 | finance.yahoo.comLIXTE BIOTECHNOLOGY HOLDINGS REPORTS NEWLY PUBLISHED INDEPENDENT PRE-CLINICAL RESEARCHFebruary 13, 2023 | finance.yahoo.comLixte Biotechnology Holdings, Inc. (LIXTW)See More Headlines Receive LIXT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lixte Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address LIXT Company Calendar Last Earnings8/09/2023Today9/20/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LIXT CUSIPN/A CIK1335105 Webwww.lixte.com Phone(631) 830-7092Fax631-982-5050Employees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,310,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-565.06% Return on Assets-124.11% Debt Debt-to-Equity RatioN/A Current Ratio7.68 Quick Ratio7.68 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.00 per share Price / Book1.95Miscellaneous Outstanding Shares2,249,000Free Float1,840,000Market Cap$4.39 million OptionableNot Optionable Beta-0.49 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. John S. Kovach M.D. (Age 86)Founder, Pres, CEO, Chief Scientific Officer & Chairman Comp: $250kMr. Robert Neal Weingarten (Age 71)VP & CFO Comp: $175kMr. Eric J. Forman J.D. (Age 44)VP & COO Comp: $178.82kDr. James S. Miser M.D. (Age 76)Chief Medical Officer Comp: $175kKey CompetitorsPanbela TherapeuticsNASDAQ:PBLAKiora PharmaceuticalsNASDAQ:KPRXObsEvaNASDAQ:OBSVCyclacel PharmaceuticalsNASDAQ:CYCCHillstream BioPharmaNASDAQ:HILSView All CompetitorsInsiders & InstitutionsGeode Capital Management LLCSold 91,090 shares on 8/11/2023Ownership: 0.606%Rene BernardsBought 1,500 shares on 12/15/2022Total: $7,650.00 ($5.10/share)Rene BernardsBought 1,000 shares on 12/12/2022Total: $6,100.00 ($6.10/share)Eric FormanBought 145 shares on 11/21/2022Total: $812.00 ($5.60/share)Regina BrownBought 500 shares on 11/21/2022Total: $2,900.00 ($5.80/share)View All Insider TransactionsView All Institutional Transactions LIXT Stock - Frequently Asked Questions How have LIXT shares performed in 2023? Lixte Biotechnology's stock was trading at $5.09 at the beginning of the year. Since then, LIXT stock has decreased by 61.7% and is now trading at $1.95. View the best growth stocks for 2023 here. Are investors shorting Lixte Biotechnology? Lixte Biotechnology saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 7,200 shares, a drop of 44.2% from the August 15th total of 12,900 shares. Based on an average daily volume of 133,800 shares, the short-interest ratio is presently 0.1 days. Approximately 0.3% of the company's stock are sold short. View Lixte Biotechnology's Short Interest. When is Lixte Biotechnology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our LIXT earnings forecast. How were Lixte Biotechnology's earnings last quarter? Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) released its quarterly earnings data on Wednesday, August, 9th. The company reported ($1.00) earnings per share (EPS) for the quarter. When did Lixte Biotechnology's stock split? Lixte Biotechnology shares reverse split on Monday, June 5th 2023. The 1-10 reverse split was announced on Monday, June 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Lixte Biotechnology IPO? (LIXT) raised $7 million in an initial public offering (IPO) on Wednesday, November 25th 2020. The company issued 1,500,000 shares at $4.75 per share. WestPark Capital and WallachBeth Capital acted as the underwriters for the IPO. What is Lixte Biotechnology's stock symbol? Lixte Biotechnology trades on the NASDAQ under the ticker symbol "LIXT." Who are Lixte Biotechnology's major shareholders? Lixte Biotechnology's stock is owned by many different retail and institutional investors. Top institutional investors include Geode Capital Management LLC (0.61%). Insiders that own company stock include Eric Forman, Regina Brown and Rene Bernards. View institutional ownership trends. How do I buy shares of Lixte Biotechnology? Shares of LIXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Lixte Biotechnology's stock price today? One share of LIXT stock can currently be purchased for approximately $1.95. How much money does Lixte Biotechnology make? Lixte Biotechnology (NASDAQ:LIXT) has a market capitalization of $4.39 million. The company earns $-6,310,000.00 in net income (profit) each year or ($3.70) on an earnings per share basis. How can I contact Lixte Biotechnology? Lixte Biotechnology's mailing address is 248 ROUTE 25A NO. 2, EAST SETAUKET NY, 11733. The official website for the company is www.lixte.com. The company can be reached via phone at (631) 830-7092, via email at info@lixte.com, or via fax at 631-982-5050. This page (NASDAQ:LIXT) was last updated on 9/21/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lixte Biotechnology Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.